Other
ALK Positive
0
Pipeline Programs↗
2
Active Trials↗
2
Companies Involved↗
ALK Positive is an early-stage landscape with 0 programs across 2 companies. The most active players are Xuanzhu Biopharmaceutical Co., Ltd., Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
5
clinical trials
Completed2 · 40%
Active, not recruiting1 · 20%
Unknown status1 · 20%
Recruiting1 · 20%
Clinical Trials
Trial Activity
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT04127110·68 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)